RxDoctor Payments Data

Nashwa Wahba, DO

Internal Medicine · Daytona Beach, FLNPI 1053753442

Payments from drug & device makers

$5,595in general payments, 2019–2025

Across 275 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Jazz Pharmaceuticals Inc.$795
  • Harmony Biosciences LLC$609
  • AstraZeneca$469
  • Sanofi$338
  • Axsome Therapeutics, Inc.$234
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,49098%
  • Education$1042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,595 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$131,243
Medicare patients
530
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter143$126,315
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$73,566
Breo ElliptaFluticasone/Vilanterol75$43,738
SymbicortBudesonide/Formoterol Fumarate70$30,410
Spiriva RespimatTiotropium Bromide25$23,577
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$10,995
Fluticasone-SalmeterolFluticasone Propion/Salmeterol51$8,369
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,996
Albuterol Sulfate HfaAlbuterol Sulfate193$7,770
Modafinil87$5,799
Advair DiskusFluticasone Propion/Salmeterol21$5,310
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$4,572
Wixela InhubFluticasone Propion/Salmeterol31$3,526
Ventolin HfaAlbuterol Sulfate33$2,388
Zolpidem Tartrate217$2,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,372$178,048229 claims
AstraZenecaBreztri Aerosphere, Symbicort$469$103,975135 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$216$34,57344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →